Neurological Takeover: NURO Gives Voice to the Voiceless by Controlling Third-Party Eye Gaze Software — Without Gaze
WATERLOO, ONTARIO, CANADA, July 9, 2025 / EINPresswire.com / -- Locked-In Patient Controls Eye-Tracking Software by Thought Alone with NURO's GRIDLY
New neurological breakthrough enables communication without eyes, speech, or movement
In a world-first, NURO has demonstrated that a completely locked-in patient suffering from a severe Anoxic Brain Injury can now control Smartbox's GRID 3 eye-tracking software purely by neurological signals — thanks to GRIDLY, NURO's revolutionary non-invasive neurotechnology.
Designed to bridge the gap between brain and software, GRIDLY allows patients with no voluntary movement or gaze control to operate existing assistive technology platforms wirelessly, instantly, and without any brain surgery. In this unprecedented case, a patient previously unable to move, speak, or use an eye-gaze system reliably, took command of the GRID 3 third-party software, using only thought.
'This is one of the most powerful demonstrations of neurological access we've ever seen,' said Francois Gand, Founder and CEO of NURO. 'GRIDLY restored a path to communication for this patient who was physiologically incompatible with an eye-gaze system. GRIDLY didn't just offer an alternative — it allowed the control of the existing system and gave it back to them as an effectively working tool.'
Smartbox's GRID 3 is widely known as a gold-standard software in Healthcare, a technology that reaches 175 countries and is implemented with more than 90,000 children and adults globally each year. However, patients with diffuse or total motor paralysis due to trauma or neurodegenerative diseases may be unable to use such systems. With GRIDLY, the dependency on eye movement, voice or any type of physical control is entirely removed, opening the door to a brand new mode of interaction, only powered by the human brain.
This clinical milestone follows NURO's growing international momentum in non-invasive neurotechnology, with deployments now spanning over 9 countries.
'With GRIDLY, we've witnessed a locked-in patient neurologically take command wirelessly of a completely separate eye-tracking system — running on a different machine, a different operating system, and designed for gaze control — without using their eyes or body at all.' added Gand.
This is also the first implementation of its kind to ever be reimbursed by Canada's WSIB, the Workers Safety Insurance Board, as the patient was originally killed by an industrial electrocution, and then clinically resuscitated at a Toronto hospital, resulting in a critical diffuse brain injury.
GRIDLY is portable, wireless, implant-free, and weighs only 38 grammes or 1.34 ounces. It can operate in hospital, rehab, or home settings. It also supports currently various integrations with leading applications running on both Microsoft Windows and the Apple operating systems.
About NURO
NURO is a Canadian neurotechnology company pioneering non-surgical, non-invasive solutions for real-time neurological communication and cognitive analysis. Its flagship systems, including NUOS 3, GRIDLY, and MENTIS, are redefining what's possible with the human brain.
Media Inquiries / Clinical Collaborations:
Francois Gand, Founder & CEO
[email protected]
www.nuro.world
Francois Gand
NURO CORP.
+1 800-841-6078
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Draft of Trump's Health Blueprint Avoids Industry Crackdown
(Bloomberg) -- A draft of the Trump administration's highly anticipated blueprint on health policy takes a softer approach to regulating companies than many had feared, a relief for industry and setback for environmental activists. The US-Canadian Road Safety Gap Is Getting Wider Festivals and Parades Are Canceled Amid US Immigration Anxiety A Photographer's Pipe Dream: Capturing New York's Vast Water System To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain The draft report, which has been reviewed by Bloomberg News, has parts that go beyond previous announcements. They are mostly about boosting research in areas such as the risks of microplastics and how antidepressants are prescribed for children. It also refers to plans to boost fertility rates and getting whole milk into public schools. The draft was dated Aug. 11, but could still see changes before it's finalized, according to people familiar with the discussions who weren't authorized to speak publicly on the matter. In particular, the report's tone around pesticides is far less critical than Health and Human Services Secretary Robert F. Kennedy Jr. and his allies have been in the past. That raised concerns earlier this week from some of his supporters in the so-called Make America Healthy Again movement, according to the people. The policy agenda is the second installment in a two-part process to carry out an executive order that President Donald Trump signed in February. The first report detailed research about what the administration viewed as the root cause of chronic disease among children, and the second was intended to lay out policies to address those root causes. The strategy was due to be submitted to the president on Aug. 12, but hasn't been publicly released. The White House declined to confirm the draft's authenticity, but industry officials said it was largely in line with what they had been briefed on by the administration. Still, the report appeared in flux before its public release, with the debate centered on the wording of the pesticide provisions. 'Until officially released by the White House and MAHA Commission, any documents purporting to be the second MAHA Report should be disregarded as speculative literature,' said White House spokesman Kush Desai. The document aligns with the administration's strategy to create change by pressuring industries, rather than through new regulations or laws. Officials have employed the strategy with food companies, health insurers and pharmaceutical producers so far. Pesticides Approach The draft takes a lighter touch on pesticides, after a backlash from the agricultural community before the first report's release prompted an internal debate over the issue. The document calls for continually evaluating the current framework to 'ensure that chemicals and other exposures do not interact together to pose a threat to the health of our children.' It references measuring the 'cumulative exposure' to chemicals. That could rankle farmers and agriculture firms, which say that pesticides are safe to use and disputes language that suggests they could be harmful to Americans. Kennedy has been skeptical of some vaccines, and the document calls for more research on vaccine injuries. The draft has vague pronouncements such as 'ensuring scientific and medical freedom' and making sure Americans have the 'best' vaccination schedule. The agency will launch a 'MAHA education campaign' to promote the early adoption of lifestyle changes that may increase fertility rates among men and women, including through new partnerships with federally funded family planning facilities, according to the draft, which didn't provide specific examples of what would be taught. Kennedy has repeatedly raised concerns over declining sperm counts and testosterone rates, especially among teenage boys, to explain declining US birth rates. Processed Foods The draft report criticizes 'highly processed foods,' listing poor diet among the top drivers of children's chronic diseases, but didn't propose any significant new restrictions on the industry. The administration has already begun the process of defining 'ultra processed foods,' which it said will be used to develop future research funding and policies. The report refers to highly processed foods more often than ultra-processed foods and doesn't distinguish between the terms. Ultra-processed foods typically involve some industrial steps or ingredients, unlike whole foods such as fruits and vegetables. Many packaged foods are generally considered ultra-processed. The report also pointed to forthcoming revised dietary guidelines, which Trump officials have estimated will be released in the fall. Kennedy has said those guidelines will encourage people to eat 'whole foods,' and will be simple and easy to understand. The draft report previews several public health awareness campaigns it plans to launch, including a 'Real Food First' push to 'prioritize whole, minimally processed foods over packaged and highly processed alternatives.' Whole Milk Food and Drug Administration Commissioner Marty Makary has indicated the dietary guidelines will take a new approach toward saturated fat. The draft report included one hint of what could be coming, by specifically calling to remove the restrictions around serving whole milk in schools. Because the current dietary guidelines recommend limiting consumption of foods high in saturated fat to less than 10% of calories daily, schools serve only skim and 1% milk. The draft calls for increased oversight and enforcement of advertisements for direct-to-consumer drugs. The report suggests that social media influencers and telehealth companies – categories that have historically fallen into a regulatory gray area – should be subject to greater oversight when promoting drugs. Lawmakers have been pressuring the federal government to take action on the influx of advertisements from telehealth companies that offer copycat weight-loss medications. That includes allegations that Hims & Hers Health Inc. omitted safety information in advertising. --With assistance from Ilena Peng, Charles Gorrivan and Madison Muller. What Declining Cardboard Box Sales Tell Us About the US Economy Americans Are Getting Priced Out of Homeownership at Record Rates Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Twitter's Ex-CEO Is Moving Past His Elon Musk Drama and Starting an AI Company How Syrian Immigrants Are Boosting Germany's Economy ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Is It Too Late to Buy Celestica Stock?
Written by Aditya Raghunath at The Motley Fool Canada Valued at a market cap of $33 billion, Celestica (TSX:CLS) is a TSX stock that has been on an absolute tear in the last 12 months, rising close to 300%. Moreover, in the past decade, Celestica stock has returned an emphatic 1,560%, crushing broader market returns by a wide margin. As past returns are not reflective of future gains, let's see if you should own this TSX tech stock at the current valuation. How did Celestica stock perform in Q2 2025? Celestica is a global electronics manufacturing services provider offering comprehensive supply chain solutions through two segments: Advanced Technology Solutions and Connectivity and Cloud Solutions. It provides design, development, manufacturing, assembly, testing, systems integration, and after-market services to original equipment manufacturers and cloud service providers. Celestica serves diverse markets, including the aerospace and defence, industrial, HealthTech, capital equipment, communications, and enterprise sectors, with particular strength in hyperscale data centre infrastructure manufacturing. Celestica stock represents a compelling investment opportunity as the company rides the unprecedented wave of AI-driven data centre expansion. The electronics manufacturing services provider delivered exceptional Q2 results, with revenue of $2.9 billion and adjusted earnings per share of $1.39, both exceeding guidance ranges. The investment thesis centers on Celestica's dominant position in networking infrastructure for hyperscale customers. Its Communications and Cloud Solutions (CCS) segment grew by 28% year-over-year, driven by explosive demand for 800G networking switches alongside continued strength in 400G products. Notably, 800G volumes reached parity with 400G in Q2, with every major 400G customer transitioning to 800G platforms. This positions Celestica to capture market share gains as hyperscalers like Google, Amazon, and Microsoft rapidly expand their AI infrastructure. Management remains optimistic about near-term growth as it forecasts revenue of $11.6 billion in 2025, an increase of 20% year over year. Comparatively, adjusted earnings are forecast to increase by 20% to $5.50 per share. Celestica reported an operating margin of 7.4% in Q2, a quarterly record and expects free cash flow to total $400 million this year. Celestica's competitive moat stems from its globally diversified manufacturing footprint across 16 countries, providing customers with supply chain resilience and geographic flexibility. The company has proven manufacturing readiness with capacity to support $3–4 billion in additional revenue across key locations, including Thailand, Mexico, and Texas. This scalability advantage is crucial as hyperscalers continue aggressive capital expenditure spending on AI infrastructure. Is the TSX stock still undervalued? Analysts tracking Celestica stock forecast revenue to rise from $9.6 billion in 2024 to $19.2 billion in 2028. Its adjusted earnings are forecast to expand from $3.88 per share to $11.2 per share in this period. Today, the TSX tech stock trades at 34 times forward earnings, which is much higher compared to its historical multiple of 10.4 times. If CLS stock is priced at 30 times forward earnings, it should trade around $336 in early 2028, indicating upside potential of 18% from current levels. The secular tailwinds supporting Celestica's growth remain robust. Hyperscaler customers are in early innings of multi-year AI infrastructure buildouts, with recent capital expenditure increases from major cloud providers validating the sustained demand environment. The upcoming transition to 1.6T networking and next-generation AI/ML compute platforms provides additional growth catalysts extending through 2026–2027. Trading at reasonable valuations despite exceptional fundamentals, Celestica stock offers investors direct exposure to the AI infrastructure boom through a proven execution partner with market-leading capabilities, strong customer relationships, and operating leverage at volume scale. The post Is It Too Late to Buy Celestica Stock? appeared first on The Motley Fool Canada. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor Canada analyst team identified what they believe are the 15 best stocks for investors to buy now… and Shopify wasn't one of them. The 15 stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 … if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,427.64!* Now, it's worth noting Stock Advisor Canada's total average return is 94%* – a market-crushing outperformance compared to 61%* for the S&P/TSX Composite Index. Don't miss out on our top 15 list, available when you join Stock Advisor Canada. See the 15 Stocks * Returns as of July 15th, 2025 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Alphabet, Amazon, and Microsoft. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
